CURE Chief Business Officer Jonathan Berlent participates in a virtual presentation at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on Thursday, June 17.
“The potential therapeutic benefits of psychedelics to treat mental health disorders is significant. I am very proud that we have been able to commence development of our psychedelics-based pharmaceutical clinical pipeline,” Berlent said. “I look forward to sharing insights on how we will take advantage of our U.S. based, DEA-licensed Schedule 1 controlled substances facility, to deliver a number of psychedelic compounds in new ways that we believe will impact disease progression and improve the patient experience.”
